Wilder-Smith C H, Hufschmid E, Thormann W
Nociception Research Group and Institute of Clinical Pharmacology, University of Berne, Switzerland.
Br J Clin Pharmacol. 1998 Jun;45(6):575-81. doi: 10.1046/j.1365-2125.1998.00727.x.
Dihydrocodeine is metabolized to dihydromorphine via the isoenzyme cytochrome P450 2D6, whose activity is determined by genetic polymorphism. The importance of the dihydromorphine metabolites for analgesia in poor metabolizers is unclear. The aim of this study was to assess the importance of the dihydromorphine metabolites of dihydrocodeine in analgesia by investigating the effects of dihydrocodeine on somatic and visceral pain thresholds in extensive and quinidine-induced poor metabolizers.
Eleven healthy subjects participated in a double-blind, randomized, placebo-controlled, four-way cross-over study comparing the effects of single doses of placebo and slow-release dihydrocodeine 60 mg with and without premedication with quinidine sulphate 50 mg on electrical, heat and rectal distension pain tolerance thresholds. Plasma concentrations and urinary excretion of dihydrocodeine and dihydromorphine were measured.
In quinidine-induced poor metabolizers the plasma concentrations of dihydromorphine were reduced between 3 and 4 fold from 1.5 h to 13.5 h after dosing (P < 0.005) and urinary excretion of dihydromorphine in the first 12 h was decreased from 0.91% to 0.28% of the dihydrocodeine dose (P < 0.001). Dihydrocodeine significantly raised the heat pain tolerance thresholds (at 3.3 h and 5 h postdosing, P < 0.05) and the rectal distension defaecatory urge (at 3.3 h and 10 h postdosing, P < 0.02) and pain tolerance thresholds (at 3.3 h and 5 h postdosing, P < 0.05) compared with placebo. Premedication with quinidine did not change the effects of dihydrocodeine on pain thresholds, but decreased the effect of dihydrocodeine on defaecatory urge thresholds (at 1.5 h, 3.3 h and 10 h postdosing, P < 0.05).
In quinidine-induced poor metabolizers significant reduction in dihydromorphine metabolite production did not result in diminished analgesic effects of a single dose of dihydrocodeine. The metabolism of dihydrocodeine to dihydromorphine may therefore not be of clinical importance for analgesia. This conclusion must however, be confirmed with repeated dosing in patients with pain.
双氢可待因通过细胞色素P450 2D6同工酶代谢为双氢吗啡,其活性由基因多态性决定。双氢吗啡代谢产物对代谢缓慢者镇痛的重要性尚不清楚。本研究的目的是通过研究双氢可待因对广泛代谢者和奎尼丁诱导的代谢缓慢者的躯体和内脏痛阈的影响,评估双氢可待因的双氢吗啡代谢产物在镇痛中的重要性。
11名健康受试者参与了一项双盲、随机、安慰剂对照、四交叉研究,比较单剂量安慰剂和60毫克缓释双氢可待因在有或没有预先服用50毫克硫酸奎尼丁的情况下对电、热和直肠扩张疼痛耐受阈的影响。测量了双氢可待因和双氢吗啡的血浆浓度及尿排泄量。
在奎尼丁诱导的代谢缓慢者中,给药后1.5小时至13.5小时,双氢吗啡的血浆浓度降低了3至4倍(P<0.005),前12小时内双氢吗啡的尿排泄量从双氢可待因剂量的0.91%降至0.28%(P<0.001)。与安慰剂相比,双氢可待因显著提高了热痛耐受阈(给药后3.3小时和5小时,P<0.05)以及直肠扩张排便冲动(给药后3.3小时和10小时,P<0.02)和疼痛耐受阈(给药后3.3小时和5小时,P<0.05)。预先服用奎尼丁并没有改变双氢可待因对痛阈的影响,但降低了双氢可待因对排便冲动阈的影响(给药后1.5小时、3.3小时和10小时,P<0.05)。
在奎尼丁诱导的代谢缓慢者中,双氢吗啡代谢产物产量的显著降低并未导致单剂量双氢可待因的镇痛效果减弱。因此,双氢可待因向双氢吗啡的代谢可能对镇痛无临床重要性。然而,这一结论必须在疼痛患者中重复给药来加以证实。